Nasdaq
$2.24▼ 3.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $30.3MShares out 13.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 1d agoAfter-hours26.10.24 06:014Ownership#●●●
CervoMed Inc.
Insider Kelly Blackburn of CervoMed Inc. reported a change in beneficial ownership of securities as of October 22, 2026. This filing is a Form 4 statement detailing the adjustment in the insider's holdings.…more
$2.24-3.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 1d agoAfter-hours26.10.24 06:014Ownership
CervoMed Inc.
CervoMed Inc. insider Mark De Rosch filed a Form 4 on October 23, 2026, reporting a change in beneficial ownership of company securities as of October 22, 2026. This filing serves as an official record of the insider's equity position adjustment.…more
$2.24-3.03%vs prev closeView filingShare - 1d agoAfter-hours26.10.24 06:004Ownership
CervoMed Inc.
Insider Winton Matthew of CervoMed Inc. filed a Form 4 report on October 22, 2026, regarding changes in beneficial ownership of securities. This filing serves as an official record of the insider's equity transactions.…more
$2.24-3.03%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12Regular26.10.13 01:13#●●●#●●●
CervoMed Reports Phase 2a Results for Aphasia Treatment
CervoMed announced positive early Phase 2a clinical data for its neflamapimod therapy, showing a reduction in nerve damage biomarkers in patients with nfvPPA. Despite the clinical progress, the company's stock price experienced a significant decline following the report.…more
$2.24-3.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.12Pre-market26.10.12 20:30
●●●●●●●● ●●●●● ●●●●●●
CervoMed announced that its neflamapimod treatment showed a reduction in neurofilament light chain levels, a key biomarker for neuronal damage, in a Phase 2a trial for nfvPPA. These are early-stage open-label results, and further clinical data and regulatory validation are required.…more
$2.24-3.03%vs prev close - 9.28Pre-market26.09.28 20:30
●●●●●●●● ●●●●● ●●●●●●
CervoMed has developed a new oral tablet formulation for its lead candidate, neflamapimod, and received FDA approval to remove previous drug exposure limits. These advancements allow for more flexible dosing regimens in future clinical trials, though the drug remains in the clinical development stage.…more
$2.24-3.03%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report